Breast cancer PDxO cultures for drug discovery and functional precision oncology
Sandra D. Scherer, Ling Zhao, Andrew Butterfield, Chieh‐Hsiang Yang, Emilio Cortes-Sanchez, Katrin P. Guillen, Bryan E. Welm, Alana L. Welm
Abstract
Patient-derived xenografts (PDXs) have clinical value but are time-, cost-, and labor-intensive and thus ill-suited for large-scale experiments. Here, we present a protocol to convert PDX tumors into PDxOs for long-term cultures amenable to moderate-throughput drug screens, including in-depth PDxO validation. We describe steps for PDxO preparation and mouse cell removal. We then detail PDxO validation and characterization and drug response assay. Our PDxO drug screening platform can predict therapy response in vivo and inform functional precision oncology for patients. For complete details on the use and execution of this protocol, please refer to Guillen et al.1